Market closed
Catalent/$CTLT
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Catalent
Catalent is a contract development and manufacturing organization, or CDMO. It operates under four segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical supply services. Catalent derives its revenues primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products throughout the entire life cycle of a product from the drug development process to commercial supply. Catalent has over 50 facilities across four continents.
Ticker
$CTLT
Sector
Trading on
NYSE
Industry
Pharmaceuticals
Headquarters
Employees
16,900
Website
Catalent Metrics
BasicAdvanced
$11B
Market cap
-
P/E ratio
-$2.28
EPS
1.16
Beta
-
Dividend rate
Price and volume
Market cap
$11B
Beta
1.16
52-week high
$63.03
52-week low
$37.03
Average daily volume
2.3M
Financial strength
Current ratio
2.512
Quick ratio
1.69
Long term debt to equity
137.945
Total debt to equity
139.3
Interest coverage (TTM)
-0.11%
Management effectiveness
Return on assets (TTM)
-0.18%
Return on equity (TTM)
-11.19%
Valuation
Price to revenue (TTM)
2.584
Price to book
3.23
Price to tangible book (TTM)
31.35
Price to free cash flow (TTM)
115.433
Growth
Revenue change (TTM)
4.71%
Earnings per share change (TTM)
-59.29%
3-year revenue growth (CAGR)
1.92%
3-year earnings per share growth (CAGR)
-10.46%
What the Analysts think about Catalent
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Catalent stock.
Catalent Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Catalent Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Catalent News
AllArticlesVideos
Novo Nordisk A/S: The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is cleared to close
GlobeNewsWire·10 hours ago
Catalent and Novo Holdings Fulfill All Regulatory Closing Conditions for Pending Transaction
Business Wire·12 hours ago
Catalent and Novo Holdings Receive European Commission Unconditional Approval for Pending Transaction
Business Wire·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Catalent stock?
Catalent (CTLT) has a market cap of $11B as of December 14, 2024.
What is the P/E ratio for Catalent stock?
The price to earnings (P/E) ratio for Catalent (CTLT) stock is 0 as of December 14, 2024.
Does Catalent stock pay dividends?
No, Catalent (CTLT) stock does not pay dividends to its shareholders as of December 14, 2024.
When is the next Catalent dividend payment date?
Catalent (CTLT) stock does not pay dividends to its shareholders.
What is the beta indicator for Catalent?
Catalent (CTLT) has a beta rating of 1.16. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.